Diabetes Mellitus (DM) is a metabolic disorder resulting from a defect in insulin secretion, insulin action or both. Data has been revealed that that >200 million people worldwide are having DM and almost it will reach to 300 million by 2025. Elevated glucose level in the blood drives to chronic complication which affects kidney, retina, heart and nervous system. Impaired insulin secretion and its resistance are the fact of non-insulin dependent DM, where as insulin deficiency as the factor of insulin dependent DM. Hormonal replacement therapy (insulin injection) is must for the later and the former type is managed by oral hypoglycemic agents. Hypoglycemic agents are shortlisted as secretagogues and insulin senziters based on their mechanism like stimulation of alpha-cells of pancreas, enhancing the peripheral uptake of glucose, diminishing the insulin resistance and inhibition of gluconeogenisis. Glucose absorption in GUT and re-absorption in the kidney were also targeted in order to get a beneficial activity. Prescription of combinational therapy is the recent trends of the physicians to get better results. Since, the status is on progress day by day, a better medicament with limited adverse effects should be bloomed to minimize the morbid status. © Medwell Journals, 2014.
cited By (since 1996)0
S.K. Kanthlal, Krishnan, R., Radhakrishnan, R., Rajalekshmy, M., Priyalakshmi, K. G., and Soman, N. P. Priya, “An updated compact review on diabetes and moleculer target of oral hypoglycemic agents”, Research Journal of Pharmacology, vol. 8, pp. 6-12, 2014.